Medications for Malignant Neoplasm Of Breast

13 results

  • abraxane

    (Paclitaxel)
    Abraxis BioScience, LLC
    ABRAXANE is indicated for treating metastatic breast cancer after chemotherapy failure, as well as for first-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with carboplatin. It is also indicated for first-line treatment of metastatic pancreatic adenocarcinoma combined with gemcitabine.

  • arimidex

    (Anastrozole)
    ANI Pharmaceuticals, Inc.
    ARIMIDEX is indicated for adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for first-line and second-line treatment of hormone receptor-positive or unknown locally advanced and metastatic breast cancer, particularly after disease progression on tamoxifen therapy.

  • cerianna

    (FLUOROESTRADIOL F 18)
    GE Healthcare Inc.
    CERIANNA is indicated for detecting estrogen receptor-positive lesions in recurrent or metastatic breast cancer using positron emission tomography (PET) imaging, as an adjunct to tissue biopsy. It is not effective for imaging other receptors like HER2 and progesterone receptor. Biopsy is required to confirm cancer recurrence and ER status.

  • faslodex

    (Fulvestrant)
    AstraZeneca Pharmaceuticals LP
    FASLODEX is indicated for treating HR-positive, HER2-negative advanced breast cancer in postmenopausal women, either as monotherapy for untreated or progressing disease, or in combination with ribociclib, palbociclib, or abemaciclib following disease progression on prior endocrine therapy.

  • herceptin

    (Trastuzumab)
    Genentech, Inc.
    Herceptin is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer in combination with paclitaxel, or as a single agent after previous regimens. It is also used with cisplatin and capecitabine for HER2-positive metastatic gastric cancer. Patient selection should utilize an FDA-approved diagnostic.

  • ibrance

    (palbociclib)
    Pfizer Laboratories Div Pfizer Inc
    IBRANCE is indicated for adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor or fulvestrant after disease progression, and with inavolisib and fulvestrant for endocrine-resistant, PIK3CA-mutated cases after adjuvant endocrine therapy.

  • ibrance

    (palbociclib)
    Pfizer Laboratories Div Pfizer Inc
    IBRANCE is indicated for adult patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor or fulvestrant, and also with inavolisib and fulvestrant for endocrine-resistant, PIK3CA-mutated cases after recurrence post-adjuvant therapy.

  • ibrance

    (palbociclib)
    U.S. Pharmaceuticals
    IBRANCE is indicated for treating adult patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, either in combination with an aromatase inhibitor as initial endocrine therapy or with fulvestrant for those with disease progression after endocrine therapy.

  • ixempra

    (ixabepilone)
    R-Pharm US Operating, LLC
    IXEMPRA is indicated for treating metastatic or locally advanced breast cancer in patients resistant to anthracyclines and taxanes. It is used in combination with capecitabine or as a single agent for patients whose tumors are resistant to anthracyclines, taxanes, and capecitabine.

  • nerlynx

    (neratinib)
    Puma Biotechnology, Inc.
    NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy, and for the treatment of advanced or metastatic HER2-positive breast cancer in adults who have received two or more prior anti-HER2 therapies.